Wulff, Hansen & Co. Abb Vie Inc. Transaction History
Wulff, Hansen & Co.
- $99.1 Million
- Q3 2024
A detailed history of Wulff, Hansen & Co. transactions in Abb Vie Inc. stock. As of the latest transaction made, Wulff, Hansen & Co. holds 2,770 shares of ABBV stock, worth $485,802. This represents 0.55% of its overall portfolio holdings.
Number of Shares
2,770
Previous 2,770
-0.0%
Holding current value
$485,802
Previous $475,000
15.16%
% of portfolio
0.55%
Previous 0.5%
Shares
8 transactions
Others Institutions Holding ABBV
# of Institutions
3,852Shares Held
1.25BCall Options Held
16.8MPut Options Held
12.2M-
Vanguard Group Inc Valley Forge, PA172MShares$30.1 Billion0.62% of portfolio
-
Black Rock Inc. New York, NY136MShares$23.9 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.1MShares$13.9 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY52.1MShares$9.14 Billion0.84% of portfolio
-
Morgan Stanley New York, NY38.7MShares$6.79 Billion0.56% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $310B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...